pipelinechart

1 Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Expected Milestones Target Patient Populations C H R O N IC N E U T R O P E N IC D IS O R D E R S (In -h ou se ) Mavorixafor WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Top-line data 4Q 2022 NDA Submission early 2H 2023 >1,000 U.S.1 Chronic Neutropenia (Congenital, Cyclic, and Idiopathic) Add’l data / regulatory update 1H 2023 ~50,000 U.S.2 X4P-003 TBD O N C O LO G Y (P ar tn er in g) Mavorixafor Waldenström’s Macroglobulinemia* (double-mutation patients) >2,000 U.S.3 X4P-002 Oncology indications* Other leukemias and lymphomas >25,000 U.S.3 Phase 3 Phase 1b Phase 1b IND-enabling *Programs only being advanced through partnership 1. Company market research. Qessential market research, 2019 and IPM.ai artificial intelligence study, 2020. 2. U.S. Prevalence Based on ICD-10 Code Research, Average Across 3 Years (2018, 2019, & 2021); >90% greater than 18 years of age, ~2/3 female, mixed G-CSF use; 3. WM Epidemiology Analysis The NemetzGroup. Exhibit 99.1